Since the founding of Neopharma, we have focused on developing and delivering medications that advance the treatment of life-threatening diseases. The commercial success of our products provides us with the resources to generate new clinical data defining their profiles and supports our development of new therapeutic advancements.

As we bring new products into clinical development, our goal remains the same–to discover, develop and commercialize therapeutics that advance patient care. Our state-of-the-art R&D center caters to both in-house and collaborative manufacturer’s needs. The R&D block houses the latest hi-tech equipment of reputed European and American brands in the industry.

Neopharma is leveraging its 'credibly capable' expertise in drug discovery and development processes, cutting- edge infrastructure as well as best-in-class manufacturing capabilities to build a unique Novel Molecules pipeline. These molecules are aimed at addressing local as well as global unmet medical needs in the areas of diabetes, malaria and oncology. Neopharma’s objective remains, to translate breakthrough innovative ideas into affordable, yet transformative, high quality medicines for patients globally.

Our pipeline is spread across the entire drug discovery and development value chain that takes advantage of our end-to-end capabilities from drug discovery through regulatory and therapeutic area expertise, built over 15 years. Through in-house discovery and strategic in – licensing partnerships, Neopharma has acquired novel molecules that span a wide range of platforms. Our skills in manufacturing processes, analytical development as well as cutting- edge translational and clinical sciences enable us to maximize the overall probability of success in the clinic.